目的 观察益心舒片联合盐酸伊伐布雷定片治疗慢性稳定型心绞痛的临床疗效。方法 选取2015年12月-2017年12月中国人民武装警察8650部队医院收治的100例慢性稳定型心绞痛患者作为研究对象，所有患者根据随机对照原则分为对照组（50例）和治疗组（50例）。对照组患者口服盐酸伊伐布雷定片，1片/次，2次/d；治疗组患者在对照组基础上口服益心舒片，3片/次，3次/d。两组患者均连续治疗12周。观察两组患者的临床疗效，比较两组治疗前后的心绞痛频率、持续时间、西雅图心绞痛量表（SAQ）评分、血清生化指标。结果 治疗后，治疗组总有效率为94.00%，显著高于对照组的78.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者心绞痛发作次数和持续时间均较明显降低，而SAQ评分显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组心绞痛发作次数、持续时间和SAQ评分显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者内皮素-1（ET-1）、可溶性CD40配体（sCD40L）水平均明显降低，而降钙素基因相关肽（CGRP）水平显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组各指标显著优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 益心舒片联合盐酸伊伐布雷定片治疗慢性稳定型心绞痛具有较好的临床疗效，能够明显改善患者临床症状和血清生化指标，具有一定的临床推广应用价值。

Objective To observe the clinical efficacy of Yixinshu Tablets combined with Ivabradine Hydrochloride Tablets in treatment of chronic stable angina pectoris.Methods Patients (100 cases) with chronic stable angina pectoris in People's Armed Police 8650 Military Hospital from December 2015 to December 2017 were randomly divided into the control group (50 cases) and treatment group (50 cases). Patients in the control group were po administered with Ivabradine Hydrochloride Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Yixinshu Tablets on the basis of the control group, 3 tablets/ time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the angina frequency, duration, SAQ scores, and serum biochemical indicators in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the treatment group was 94.00%, which was significantly higher than 78.00% in the control group, and there were differences between two groups (P<0.05). After treatment, angina frequency and duration in two groups were significantly decreased, but SAQ scores were increased, and the difference was statistically significant in the same group (P<0.05). And angina frequency, duration and SAQ scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, ET-1 and sCD40L levels in two groups were significantly decreased, but CGRP levels were increased, and the difference was statistically significant in the same group (P<0.05). And those indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05).Conclusion Yixinshu Tablets combined with Ivabradine Hydrochloride Tablets has good clinical efficacy in treatment of chronic stable angina pectoris, can significantly improve the clinical symptoms and serum biochemical indexes, which has a high clinical research value.